Noriko Fukuhara

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima et al. · Neuro-Oncology · 2020 · 184 citations · Full text

Medicine, Oncology, Pharmacology +17

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial

Kazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta et al. · The Lancet Oncology · 2020 · 97 citations

Medicine, Oncology, Pharmacotherapy +15

Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification

Ichiro Yonese, Chizuko Sakashita, Ken‐Ichi Imadome et al. · Blood Advances · 2020 · 97 citations · Full text

Medicine, Infectious Diseases, Oncology +11